The agreement is on a modified mesenchymal stem cell preparation (SB623) for the treatment of chronic cerebral infarctions. Teijin, who is invested in SanBio, had initiated discussions with the Pharmaceuticals and Medical Devices Agency (PMDA) since 2012 and developed, in 2016, consultations on clinical development plan aiming for early approval. Based on differences in development policy between the two companies, the license agreement will be canceled and SanBio will further develop this cell medicine for indications such as chronic cerebral infarction.
Source: SanBio Inc. news release, February 14, 2018
Request a quote for deeper information from